Showing posts with label J147. Show all posts
Showing posts with label J147. Show all posts

Sunday, April 29, 2018

Seven brain benefits of turmeric

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]



Salk Institute's J147 is a derivative of turmeric, a spice used in curry. Learn how it quickly reverses memory deficits and has a host of unexpected anti-aging effects in the lab. 




Salk Institute researchers have found that J147, which is an experimental drug candidate aimed at combating Alzheimer's disease, has a host of unexpected anti-aging effects in animals.

J147, Alzheimer's and Old Age

The Salk team expanded upon their previous development of the drug candidate they labeled J147. It is a derivative of the common spice, turmeric, and takes a different tack by targeting Alzheimer's major risk factor -- old age. In the new work, the team showed that the drug candidate worked well in a mouse model of aging not typically used in Alzheimer's research. When these mice were treated with J147, they had better memory and cognition, healthier blood vessels in the brain and other improved physiological features, as detailed in the journal Aging.

Fighting Alzheimer's By Fighting Aging

"Initially, the impetus was to test this drug in a novel animal model that was more similar to 99 percent of Alzheimer's cases," says Antonio Currais, the lead author and a member of Professor David Schubert's Cellular Neurobiology Laboratory at Salk. "We did not predict we'd see this sort of anti-aging effect, but J147 made old mice look like they were young, based upon a number of physiological parameters."

Alzheimer's disease is a progressive brain disorder, recently ranked as the third leading cause of death in the United States and affecting more than five million Americans. It is also the most common cause of dementia in older adults, according to the National Institutes of Health.

"While most drugs developed in the past 20 years target the amyloid plaque deposits in the brain (which are a hallmark of the disease), none have proven effective in the clinic," says Schubert, senior author of the study.

Expanding the Fight to More Common Dementias

Several years ago, Schubert and his colleagues began to approach the treatment of the disease from a new angle. Rather than target amyloid, the lab decided to zero in on the major risk factor for the disease--old age. Using cell-based screens against old age-associated brain toxicities, they synthesized J147.

Previously, the team found that J147 could prevent and even reverse memory loss and Alzheimer's pathology in mice that have a version of the inherited form of Alzheimer's, the most commonly used mouse model. However, this form of the disease comprises only about 1 percent of Alzheimer's cases. For everyone else, old age is the primary risk factor, says Schubert. The team wanted to explore the effects of the drug candidate on a breed of mice that age rapidly and experience a version of dementia that more closely resembles the age-related human disorder.

Young Mice, Old Mice and J147-fed Mice

In this latest work, the researchers used a comprehensive set of assays to measure the expression of all genes in the brain, as well as over 500 small molecules involved with metabolism in the brains and blood of three groups of the rapidly aging mice. The three groups of rapidly aging mice included one set that was young, one set that was old and one set that was old but fed J147 as they aged.

7 Benefits

The old mice fed J147 saw the following benefits:
  1. They performed better on memory and other tests for cognition
  2. They displayed more robust motor movements.
  3. They had fewer pathological signs of Alzheimer's in their brains.
  4. J147 prevented the leakage of blood from the microvessels in the brains of old mice. "Damaged blood vessels are a common feature of aging in general, and in Alzheimer's, it is frequently much worse," says Currais.

    Importantly, because of the large amount of data collected on the three groups of mice, it was possible to demonstrate that many aspects of gene expression and metabolism in the old mice fed J147 were very similar to those of the young animals. These included:
  5. markers for increased energy metabolism,
  6. reduced brain inflammation and
  7. reduced levels of oxidized fatty acids in the brain.

Human Clinical Trials

Currais and Schubert note that while these studies represent a new and exciting approach to Alzheimer's drug discovery and animal testing in the context of aging, the only way to demonstrate the clinical relevance of the work is to move J147 into human clinical trials for Alzheimer's disease.

"If proven safe and effective for Alzheimer's, the apparent anti-aging effect of J147 would be a welcome benefit," adds Schubert. The team aims to begin human trials next year.


Thursday, April 20, 2017

7 Brain Benefits of Turmeric Derivative for Dementia Prevention

Caregivers, and healthcare professionals,here is some great information

Here is a great 
dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best 
caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow 
alzheimersideas on twitter


The Dementia Caregiver's Little Book of Hope [Kindle Edition


The Salk team expanded upon their previous development of a drug candidate, called J147, which takes a different tack by targeting Alzheimer's major risk factor--old age. In the new work, the team showed that the drug candidate worked well in a mouse model of aging not typically used in Alzheimer's research. When these mice were treated with J147, they had better memory and cognition, healthier blood vessels in the brain and other improved physiological features, 

"Initially, the impetus was to test this drug in a novel animal model that was more similar to 99 percent of Alzheimer's cases," says Antonio Currais, the lead author and a member of Professor David Schubert's Cellular Neurobiology Laboratory at Salk. "We did not predict we'd see this sort of anti-aging effect, but J147 made old mice look like they were young, based upon a number of physiological parameters."

Alzheimer's disease is a progressive brain disorder, recently ranked as the third leading cause of death in the United States and affecting more than five million Americans. It is also the most common cause of dementia in older adults, according to the National Institutes of Health.

"While most drugs developed in the past 20 years target the amyloid plaque deposits in the brain (which are a hallmark of the disease), none have proven effective in the clinic," says Schubert, senior author of the study.

Expanding the Fight to More Common Dementias

Several years ago, Schubert and his colleagues began to approach the treatment of the disease from a new angle. Rather than target amyloid, the lab decided to zero in on the major risk factor for the disease--old age. Using cell-based screens against old age-associated brain toxicities, they synthesized J147.

Previously, the team found that J147 could prevent and even reverse memory loss and Alzheimer's pathology in mice that have a version of the inherited form of Alzheimer's, the most commonly used mouse model. However, this form of the disease comprises only about 1 percent of Alzheimer's cases. For everyone else, old age is the primary risk factor, says Schubert. The team wanted to explore the effects of the drug candidate on a breed of mice that age rapidly and experience a version of dementia that more closely resembles the age-related human disorder.

Young Mice, Old Mice and J147-fed Mice

In this latest work, the researchers used a comprehensive set of assays to measure the expression of all genes in the brain, as well as over 500 small molecules involved with metabolism in the brains and blood of three groups of the rapidly aging mice. The three groups of rapidly aging mice included one set that was young, one set that was old and one set that was old but fed J147 as they aged.

7 Benefits

The old mice fed J147 saw the following benefits:
  1. They performed better on memory and other tests for cognition
  2. They displayed more robust motor movements.
  3. They had fewer pathological signs of Alzheimer's in their brains.
  4. J147 prevented the leakage of blood from the microvessels in the brains of old mice. "Damaged blood vessels are a common feature of aging in general, and in Alzheimer's, it is frequently much worse," says Currais.

    Importantly, because of the large amount of data collected on the three groups of mice, it was possible to demonstrate that many aspects of gene expression and metabolism in the old mice fed J147 were very similar to those of the young animals. These included:
  5. markers for increased energy metabolism,
  6. reduced brain inflammation and
  7. reduced levels of oxidized fatty acids in the brain.

Human Clinical Trials

Currais and Schubert note that while these studies represent a new and exciting approach to Alzheimer's drug discovery and animal testing in the context of aging, the only way to demonstrate the clinical relevance of the work is to move J147 into human clinical trials for Alzheimer's disease.

"If proven safe and effective for Alzheimer's, the apparent anti-aging effect of J147 would be a welcome benefit," adds Schubert. The team aims to begin human trials next year.

Related Article:

Curry Derivative J147 Beats Aricept for Alzheimer's

MORE INFORMATION:

  • Other authors on the paper include Oswald Quehenberger of the University of California, San Diego; and Joshua Goldberg, Catherine Farrokhi, Max Chang, Marguerite Prior, Richard Dargusch, Daniel Daugherty and Pamela Maher of the Salk Institute.
  • This study was supported by the Salk Institute Pioneer Fund Postdoctoral Scholar Award and the Salk Nomis Fellowship Award, fellowships from the Hewitt Foundation and Bundy Foundation, and grants from the Burns Foundation and NIH.
SOURCE:

Tuesday, January 3, 2012

New drug may stop the progression of Alzheimer's disease

Here is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

Medical News Today

According to findings in a study published in PLoS One, a new drug candidate may be the first drug that is capable of halting the devastating mental decline of Alzheimer's disease. Researchers administered the drug, known as J147, to mice with Alzheimer's disease and observed an associated improvement in memory and prevention in brain damage. The new drug was developed by scientists at the Salk Institute for Biological Studies, led by David Schubert, and could be trialled as a treatment for Alzheimer's disease in humans in the near future.

David Schubert, head of Salk's Cellular Neurobiology Laboratory, explained:

"J147 enhances memory in both normal and Alzheimer's mice and also protects the brain from the loss of synaptic connections. No drugs on the market for Alzheimer's have both of these properties."


The researchers say that even though the new compound's efficacy and safety in humans has not yet been established, the results indicate that the drug could become a potential treatment in people with Alzheimer's. 



 According to figures of the National Institutes of Health, a staggering 5.4 million Americans suffer from Alzheimer's. The Alzheimer's Association estimates that by 2050 more than 16 million will be affected by the disease, resulting in annual medical costs of over $1 trillion. 


Alzheimer's causes a steady, irreversible decline in brain function. Affected individuals experience a progressive loss of memory and ability to think clearly, which subsequently leads to the person being unable to perform simple tasks, such as eating and talking, and ultimately ends in death.

Alzheimer's is associated with aging, with a typical onset in individuals aged 60 years or above, although a small percentage of families carry a genetic risk for earlier onset. Amongst the top ten causes of mortality, Alzheimer's is the only disease that cannot be prevented, cured or reduced to progress slowly.

Onset of Alzheimer's seems to be influenced by a complex mixture of genetics, lifestyle factors and environment, although scientists still remain unclear what causes the disease. Until now, drugs developed for the treatment of Alzheimer's, such as Aricept, Razadyne and Exelon have only produced short periods of memory improvements, yet do not halt the overall progression of the disease.

Schubert and his team set out to find a new type of drug, but instead of following the current trend of the pharmaceutical industry, they decided to take a different approach. The pharmaceutical industry seems to focus exclusively on the biological pathways involved in the formation of amyloid plaques, the dense deposits of protein, which characterize the disease, but according to Schubert, until now, all amyloid-based drugs have failed in clinical trials.

Instead, they developed methods in which they used living neurons grown in laboratory dishes to assess the probability of whether or not new synthetic compounds prove effective in protecting the brain cells against several pathologies connected with brain aging. Based on the test results from each chemical iteration of the lead compound, a test originally designed for treating stroke and traumatic brain injuries, Schubert and his team managed to alter its chemical structure to produce a much more potent Alzheimer's drug. 



Marguerite Prior, a research associate in Schubert's lab, who led the project together with Qi Chen, a former Salk postdoctoral researcher, explained:

"Alzheimer's is a complex disease, but most drug development in the pharmaceutical world has focused on a single aspect of the disease - the amyloid pathway. In contrast, by testing these compounds in living cell cultures, we can determine what they do against a range of age-related problems and select the best candidate that addresses multiple aspects of the disease, not just one."




 The researchers subsequently tested their promising J147 compound as an oral medication in mice. In collaboration with Amanda Roberts, a professor of molecular neurosciences at The Scripps Research Institute, they performed a series of behavioral tests, which demonstrated that the drug improved memory in normal rodents. 


They subsequently demonstrated that J147 prevented cognitive decline in animals with Alzheimer's and also proved that mice and rats treated with the drug produced more of a protein called brain-derived neurotrophic factor (BDNF). BDNF is a molecule involved in memory formation and protects neurons from toxic insults. It also helps in the growths of new neurons and connects with other brain cells.

According to the researchers, based on the compounds broad ability to protect nerve cells, J147 may also be effective in the treatment of other neurological disorders, including Parkinson's and Huntingdon's disease as well as amyotrophic lateral sclerosis (ALS), and stroke.

The research was supported through funding by the Fritz B. Burns Foundation, the National Institutes of Health, the Bundy Foundation and the Alzheimer's Association.

Written by Petra Rattue

View drug information on ARICEPT; Exelon.

Copyright: Medical News Today
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info